Very briefly, maintenance approvals are focused on patients with response to platinum used for relapse, while treatment approvals are focused on pretreated patients with deleterious BRCA1/2 mutated epithelial ovarian cancer, both for platinum-resistant or sensitive relapses. Here, BRCA1 is linked to ovarian carcinoma.